Obesity and insulin resistance enjoy a complex relationship that gives rise
to a range of metabolic disorders, including type 2 diabetes, dyslipidemia
and coagulation disorders. Teasing apart this relationship could yield new
therapies to treat some of these conditions and two new reports point to t
he adipocyte-secreted protein, adiponectin, as a new molecular target.